Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Dec 18;20(1):28–55. doi: 10.1038/s44320-023-00004-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. Creative Commons Public Domain Dedication waiver http://creativecommons.org/publicdomain/zero/1.0/ applies to the data associated with this article, unless otherwise stated in a credit line to the data, but does not extend to the graphical or creative elements of illustrations, charts, or figures. This waiver removes legal barriers to the re-use and mining of research data. According to standard scholarly practice, it is recommended to provide appropriate citation and attribution whenever technically possible.

PMC Copyright notice

Figure EV4 — (A) SPRY2 protein levels as a marker for sensitivity towards Binimetinib (left panel) and GIGYF2 S275 phosphorylation abundance as a sensitivity marker for Selumetinib (right panel; both drugs are MAP2K inhibitors). (B–D) Same as panel (A) but for Rapamycin (mTOR inhibitor) and Barasertib (PARP inhibitor). (E) The response of two Ewing sarcoma lines (in red and pink) towards AURK and PARP inhibitors is more pronounced than for all other cell lines. (F, G) Same as panel A but for Talazoparib (PARP inhibitor). Again, the two Ewing sarcoma lines (in red and pink) are the most sensitive to this drug.